GreenMark Biomedical wins follow-on regenerative medicine funding

GreenMark Biomedical received up to $297,615 in follow-on funding from the Translational Resource Center to advance regenerative products aimed at noninvasive treatment of early-stage dental decay. The grant extends work with dental schools and research partners at Michigan, Pittsburgh and Harvard as the company pushes toward a $5 million Series A round.

Why it matters: - The award adds outside validation for GreenMark Biomedical’s approach to treating early dental decay without drilling. - The funding supports development of products designed to rebuild enamel before cavities form, which could reduce invasive dental procedures. - The work also targets dental sensitivity, a common problem that can affect comfort during routine and restorative care.

What happened: - GreenMark Biomedical said its project, “Targeted Remineralization Treatment Using Mineral Loaded Starch Nanoparticles,” was selected for additional funding by the Translational Resource Center. - The company will receive up to $297,615 in follow-on funding. - The grant will help advance new forms of GreenMark’s regenerative products for noninvasive mineralization of early-stage dental decay. - The follow-on grant involves dental schools at the University of Michigan and the University of Pittsburgh, plus the Wyss Institute at Harvard. - The announcement was made in Ann Arbor, Michigan, on Aug. 25, 2026.

The details: - Since 2018, the NIH-funded center has provided GreenMark ongoing funding and access to expertise, resources, regulatory guidance, clinical input and commercialization support. - The Translational Resource Center works with a partner resource center that includes the dental school at the University of Southern California, University of California institutions and Stanford University. - GreenMark said dental caries is the world’s most prevalent chronic disease and affects more than 95% of Americans over their lifetimes. - Untreated early enamel damage can progress into painful cavities that require invasive dental procedures. - Current topical fluoride products can slow decay, but they do not fully restore enamel structure beneath the tooth surface. - Dental sensitivity affects up to 74% of Americans and can create discomfort during dental procedures. - Dr. Nathan Jones, GreenMark vice president of technology and co-principal investigator on the award, said the company is developing professional-use and over-the-counter products designed to reverse early decay by restoring enamel from the inside out. - Jones said the targeted approach also is intended to relieve dental sensitivity. - GreenMark’s CrystLCare dental strips have generated clinical and market experience with the company’s targeted mineral-forming technology. - Pilot evaluations showed rapid relief of dental sensitivity tied to gingival recession and procedures including hygiene treatment, scaling and root planing, and tooth whitening. - Clinical observations also showed radiographic evidence consistent with remineralization of early-stage caries lesions. - Rachel Miller, GreenMark’s clinical director, said the simplicity of the strips allows dental assistants to apply them chairside and lets patients continue the routine at home. - Jeff Durrbeck, GreenMark’s chief revenue officer, said training clinic staff who tried the strips themselves helped them understand how the product could be used for sensitive patients. - Dr. Steven Bloembergen, GreenMark chairman and CEO, said the funding will help advance the product pipeline and that the company is focused on closing a $5.0 million Series A round.

Between the lines: - The grant suggests GreenMark’s technology is moving beyond early research and into a broader translational stage. - The company is using the new funding to strengthen manufacturing scale-up and distribution plans, which signals a push toward commercialization. - The emphasis on sensitivity relief and chairside use positions the product as both a clinical tool and a patient-adherence aid. - The reference to a Series A round shows GreenMark still needs additional capital to expand production and reach more dental practices.

What’s next: - GreenMark will use the funding to further develop its regenerative product pipeline. - The company is seeking the remaining capital needed to complete its $5.0 million Series A round. - GreenMark says the next steps include manufacturing scale-up and broader distribution of its products. - More information is available in the company’s announcement.

The bottom line: - GreenMark just got another funding boost for a dental technology platform that aims to repair early decay, ease sensitivity and move closer to market.